NCT06149390View on ClinicalTrials.gov

ASCT Versus Chemotherapy as First-Line Consolidation Therapy inT-Cell Lymphoma

CompletedOBSERVATIONAL
Enrollment

347

Participants

Timeline

Start Date

January 1, 2014

Primary Completion Date

January 1, 2022

Study Completion Date

July 1, 2023

Conditions
T-cell Lymphoma Adults
Interventions
DRUG

consolidation with ASCT

high dose chemotherapy （BCNU, etoposide, cytarabine and melphalan)）and auto stem cells transfusion

All Listed Sponsors
collaborator

Peking University People's Hospital

OTHER

collaborator

Ruijin Hospital

OTHER

collaborator

West China Hospital

OTHER

lead

Huazhong University of Science and Technology

OTHER

NCT06149390 - ASCT Versus Chemotherapy as First-Line Consolidation Therapy inT-Cell Lymphoma | Biotech Hunter | Biotech Hunter